In AD, new therapeutic targets have been explored that focus on the modulation of the cholinergic pathway by administration of acetylcholinesterases inhibitors, α7 nAChR agonists, and vagus nerve stimulation. The gene discussed is ACHE; the disease is Alzheimer disease.